Doctors Note Logo

Published on: 3/12/2026

Still Suffering? Why Your Proctosigmoiditis Is Refractory & New Medical Next Steps

There are several factors to consider; see below to understand more.

Persistent symptoms despite optimized mesalamine and steroids may reflect inadequate rectal drug reach, undertreatment or adherence issues, steroid dependence, disease extension, or infection, and next steps include objective reassessment plus escalation to advanced therapies such as biologics (anti-TNF, vedolizumab, ustekinumab), oral small molecules (JAK inhibitors, ozanimod), and consideration of investigational options or clinical trials.

answer background

Explanation

Still Suffering? Why Your Proctosigmoiditis Is Refractory & New Medical Next Steps

If you're still dealing with rectal bleeding, urgency, mucus, or abdominal discomfort despite treatment, you're not alone. Proctosigmoiditis — a form of ulcerative colitis (UC) affecting the rectum and sigmoid colon — can sometimes become refractory, meaning it doesn't respond adequately to standard therapies.

This can be frustrating and discouraging. But refractory disease does not mean untreatable. It means it's time to reassess and consider new strategies — including investigational drugs for refractory proctosigmoiditis and advanced therapies.

Let's walk through why this happens and what medical next steps may help.


What Does "Refractory" Proctosigmoiditis Mean?

In medical terms, "refractory" usually means:

  • Symptoms persist despite appropriate doses of first-line therapy
  • You relapse quickly after tapering steroids
  • You cannot tolerate standard medications
  • Inflammation remains visible on colonoscopy

For proctosigmoiditis, first-line treatments typically include:

  • Topical mesalamine (5-ASA) suppositories or enemas
  • Oral mesalamine
  • Topical corticosteroids
  • Short courses of oral steroids

If these fail, your condition may be classified as steroid-dependent or steroid-refractory, which requires escalation of therapy.


Why Your Proctosigmoiditis May Not Be Improving

There are several common reasons treatment may not be working:

1. Inadequate Drug Delivery

Rectal therapies must physically reach inflamed tissue.

  • Suppositories treat mostly the rectum
  • Enemas reach higher into the sigmoid colon

If inflammation extends farther than expected, therapy may not be reaching the full area.

2. Under-Treated Inflammation

Low doses or inconsistent use of medications can limit effectiveness. Adherence matters — especially with rectal therapies.

3. Steroid Dependence

If symptoms return as soon as steroids are tapered, the immune response is still active and requires a more targeted long-term solution.

4. Misclassification

Occasionally:

  • Disease extent has progressed
  • Infection (like C. difficile) is present
  • Another condition is overlapping

Repeat evaluation may be necessary.


When It's Time to Escalate Treatment

If you've failed optimized mesalamine and steroid therapy, guidelines from major gastroenterology societies recommend moving to advanced immune-targeting therapies.

These include:

  • Biologic therapies
  • Small molecule drugs
  • Investigational drugs for refractory proctosigmoiditis

Escalation is not a failure — it's simply the next appropriate medical step.


Advanced & Investigational Drugs for Refractory Proctosigmoiditis

Here's what your gastroenterologist may discuss.


1. Biologic Therapies

Biologics target specific immune pathways that drive inflammation.

Anti-TNF Agents

  • Infliximab
  • Adalimumab
  • Golimumab

These block tumor necrosis factor (TNF), a key inflammatory protein.

Pros:

  • Effective for moderate-to-severe UC
  • Long track record
  • Can induce and maintain remission

Considerations:

  • Infection risk
  • Require monitoring
  • Administered by injection or infusion

Anti-Integrin Therapy (Gut-Selective)

Vedolizumab works primarily in the gut, limiting systemic immune suppression.

Pros:

  • Lower overall infection risk
  • Effective for steroid-dependent disease

IL-12/23 Inhibitor

Ustekinumab targets interleukin pathways involved in inflammation.

Pros:

  • Effective in biologic-experienced patients
  • Favorable safety profile

2. Small Molecule Therapies (Oral Options)

These are newer and increasingly used for refractory cases.

JAK Inhibitors

  • Tofacitinib
  • Upadacitinib

They block Janus kinase pathways that promote inflammation.

Advantages:

  • Oral pill
  • Rapid symptom relief in some patients

Risks:

  • Blood clots (rare but serious)
  • Infection risk
  • Requires monitoring

S1P Receptor Modulator

  • Ozanimod

Helps reduce immune cell migration to the gut.

Benefits:

  • Oral option
  • Effective for moderate-to-severe UC

3. Investigational Drugs for Refractory Proctosigmoiditis

Clinical research is expanding rapidly. Investigational drugs for refractory proctosigmoiditis focus on:

  • More selective immune targeting
  • Improved safety profiles
  • Faster onset of action
  • Precision medicine approaches

Examples of emerging targets include:

  • IL-23 specific inhibitors
  • TYK2 inhibitors
  • Novel JAK pathway modulators
  • Microbiome-based therapies
  • Stem cell approaches (early-stage research)

Clinical trials may offer access to these therapies before full approval. If standard treatments have failed, asking your gastroenterologist about clinical trial eligibility may be reasonable.


Important: Re-Evaluation Before Escalation

Before moving to advanced therapy, your doctor may:

  • Repeat colonoscopy or sigmoidoscopy
  • Check inflammatory markers (CRP, fecal calprotectin)
  • Rule out infections
  • Confirm medication adherence
  • Evaluate disease severity and extent

This ensures the right therapy is chosen.


Non-Medication Factors That Matter

Medication is critical — but it's not the only factor.

Consider:

  • Avoiding NSAIDs (which can worsen UC)
  • Managing stress (stress does not cause UC but can worsen symptoms)
  • Optimizing sleep
  • Working with a dietitian if certain foods trigger symptoms

Diet alone cannot cure refractory proctosigmoiditis, but symptom management strategies can reduce flare burden.


When Is Surgery Considered?

For severe, persistent disease that does not respond to multiple advanced therapies, colectomy (removal of the colon) may be discussed.

This is typically reserved for:

  • Severe refractory disease
  • High-grade dysplasia or cancer risk
  • Life-threatening complications

While surgery can be life-changing, it is generally considered only after exhausting medical options.


How Do You Know If Your Disease Is Truly Active?

Sometimes symptoms persist even when inflammation is controlled. This may reflect:

  • Irritable bowel syndrome overlap
  • Rectal hypersensitivity
  • Pelvic floor dysfunction

Objective testing helps differentiate active inflammation from functional symptoms.

If you're unsure whether your current symptoms indicate active inflammation or something else, using a free Ulcerative Colitis symptom checker can help you identify patterns and prepare informed questions for your next gastroenterology appointment.


When to Seek Urgent Care

Seek immediate medical attention if you experience:

  • Severe abdominal pain
  • Fever with worsening symptoms
  • Heavy rectal bleeding
  • Signs of dehydration
  • Rapid heart rate
  • Weakness or fainting

These may signal a serious complication requiring urgent evaluation.

Always speak to a doctor promptly if symptoms feel severe, rapidly worsening, or concerning.


A Practical Next-Step Plan

If your proctosigmoiditis remains refractory, consider discussing:

  • ✅ Whether inflammation is confirmed objectively
  • ✅ Optimization of topical + oral therapy
  • ✅ Transition to biologics
  • ✅ Oral small molecule options
  • ✅ Eligibility for investigational drugs for refractory proctosigmoiditis
  • ✅ Clinical trial participation
  • ✅ Multidisciplinary care (GI specialist, dietitian, mental health support)

The Bottom Line

Refractory proctosigmoiditis is challenging — but it is not hopeless.

The treatment landscape for ulcerative colitis has changed dramatically in the past decade. Multiple biologics, small molecules, and investigational drugs for refractory proctosigmoiditis are expanding the options available.

If your current plan is not working:

  • Reassess
  • Escalate thoughtfully
  • Ask about advanced therapies
  • Explore clinical trials

Most importantly, do not manage this alone. Persistent inflammation can lead to complications if untreated. Speak openly with your gastroenterologist about your ongoing symptoms and concerns.

Effective control is possible — but it may require a new approach.

(References)

  • * Al-Brahim T, Al-Nassar M, Alfadhli A, Al-Otaibi S, Al-Fadhli B, Al-Hussaini A, Al-Bahar F, Akbar M, Al-Attar K, Al-Taiar A. Vedolizumab in ulcerative proctosigmoiditis refractory to anti-TNF therapy: a single-center experience. World J Gastroenterol. 2018 Jul 7;24(25):2796-2802. doi: 10.3748/wjg.v24.i25.2796. PMID: 30018485; PMCID: PMC6035978.

  • * Söderholm JD, Olén O, Sjöberg D. Mechanisms of therapy failure in inflammatory bowel disease. Frontline Gastroenterol. 2019 Apr;10(2):123-128. doi: 10.1136/flgastro-2018-101140. Epub 2019 Jan 10. PMID: 30976315; PMCID: PMC6443424.

  • * Ko HM, Kim HS, Lee HS, Lee HJ, Lee SY, Jeon SR, Park YS, Kim YS, Chung SY, Choi CH, Eun CS, Han DS, Kim TJ. New therapeutic options for ulcerative colitis: an update. Int J Colorectal Dis. 2020 Jan;35(1):1-16. doi: 10.1007/s00384-019-03460-2. Epub 2019 Nov 16. PMID: 31734685.

  • * Olén O, Sjöberg D, Söderholm JD. Management of inflammatory bowel disease: current and future therapies. Nat Rev Gastroenterol Hepatol. 2021 Jan;18(1):15-32. doi: 10.1038/s41575-020-00366-0. Epub 2020 Oct 8. PMID: 33029015.

  • * Lamb CA, Lim AG, Lindsay JO, Mansfield JC, Irving PM, Smith PJ, Srivastava A, Saxena S, Hart AL, Goodhand JR. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J Crohns Colitis. 2022 Feb 10;16(2):167-184. doi: 10.1093/ecco-jcc/jjab178. PMID: 34160424.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Learn more about diseases

Ulcerative Colitis

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.